Overview

GSK1349572 Repeat Dose Escalation and Relative Bioavailability Study

Status:
Completed
Trial end date:
2008-06-01
Target enrollment:
Participant gender:
Summary
This is a repeat dose escalation study of GSK1349572 followed by a relative bioavailability study comparing tablet and suspension formulations in healthy volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
ViiV Healthcare
Treatments:
Dolutegravir